Detailansicht

Wissensnetz

Person

Juan W. Valle

Onkologe

Name	Juan W. Valle
Ort	Manchester (Wirkungsort) Großbritannien
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof.
Beruf	Onkologe (charakteristischer Beruf)
Beziehung	Victoria University of Manchester. Faculty of Medicine
Weitere Angaben	Prof. an der Medizinische Onkologie der Universität von Manchester (Abteilung für Krebswissenschaften, Fakultät für Biologie, Medizin und Gesundheit)
Datensatztyp	Person
GND-Nummer	1218237260
Datensatz-ID	1218237260
Beteiligt an alle anzeigen Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA Reply to Comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic” Current and novel therapeutic opportunities for systemic therapy in biliary cancer Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position Cholangiocarcinoma 2020: the next horizon in mechanisms and management NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015 Unusual skull base metastasis from neuroendocrine tumor: a case report Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial) Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC) Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary 68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients' Management HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Juan W. Valle

Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease

Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter

Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study

External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial

Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

Reply to Comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic”

Current and novel therapeutic opportunities for systemic therapy in biliary cancer

Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials

Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms

Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration

Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015

Unusual skull base metastasis from neuroendocrine tumor: a case report

Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas

Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial)

Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms

Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC)

Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy

Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets

Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma

Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients' Management

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial

Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study

A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study